TUESDAY | AUGUST 30
4:00 Personalized, Neoantigen-Based Immunotherapy
Edward Fritsch, Ph.D., Chief Technology Officer, Neon Therapeutics, Inc.
Multiple lines of evidence have demonstrated the critical role that Neoantigens have in the immune response to cancer and the availability of next-generation sequencing to identify personal, neoantigen-creating mutations has opened the door to directly enhance the power and breadth of host immunity to overcome this deadly disease.
4:30 Emerging Innate Immune Targets for Enhancing Adaptive Anti-Tumor Responses
Michael Rosenzweig, Ph.D., Executive Director, Biology-Discovery, IMR Early Discovery, Merck Research Laboratories
Novel cancer immunotherapies targeting T cell checkpoint proteins have emerged as powerful tools to induce profound, durable regression and remission of many types of cancer. Despite these advances, multiple studies have demonstrated that not all patients respond to these therapies, and the ability to predict which patients may respond is limited. Harnessing the innate immune system to augment the adaptive anti-tumor response represents an attractive target for therapy, which has the potential to enhance both the percentage and rate of response to checkpoint blockade.
5:00 Reading Tea Leaves:
The Dilemma of Prediction and Prognosis in Immunotherapy
Morganna Freeman, D.O., Associate Director, Melanoma & Cutaneous Oncology Program, The Angeles Clinic and Research Institute
With the rapid expansion of immunotherapeutics
in oncology, scientifically significant
advances have been made with both the depth
and duration of antitumor responses. However,
not all patients benefit, or quickly relapse, thus
much scientific inquiry has been devoted to
appropriate patient selection and how such
obstacles might be overcome. While more is
known about potential biomarkers, accurate
prognostication persists as a knowledge gap,
and efforts to bridge it will be discussed here.